All News

The value proposition is becoming increasingly important; it must be highly visible and cut to the chase.

Are there enough primary care physicians qualified for patient-centered medical homes? The standards need to be re-examined.

The healthcare industry is taking note as CER continues to evolve.

The sustainable growth rate formula first came on the scene during the Clinton administration, but has since derailed. Is there a way to right the wrongs?

ACOs are continuing to evolve. This week, we take a look at the latest information available.

As the FDA continues to work on the biosimilars approval process, there are growing concerns that a true cost-savings can't be realized.

A study of cost trends for tumor necrosis factor (TNF) inhibitors for rheumatoid arthritis (RA) after the entry of new competition showed that the newer drugs did not lower costs, and in fact, the annual treatment costs of the existing medicines rose by $17,390. Taxpayer funds shouldered all of the increases, and the “findings illustrate a market failure contributing to the rising costs of prescription drugs,” according to the researchers.